Electroencephalogram effects of armodafinil: Comparison with behavioral alertness

Development of central nervous system‐acting drugs would be enhanced by suitable biomarkers that reflect the targeted pathophysiologic brain state. The electroencephalogram (EEG) has several characteristics of an ideal biomarker and can be promptly adapted to pre‐clinical and clinical testing. The a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2013-10, Vol.53 (10), p.1058-1071
Main Authors: Conrado, Daniela J., Bewernitz, Michael, Ding, Mingzhou, Cibula, Jean, Seubert, Christoph, Sy, Sherwin K. B., Eisenschenk, Stephan, Derendorf, Hartmut
Format: Article
Language:English
Subjects:
Adult
alertness
armodafinil
Behavior - drug effects
Benzhydryl Compounds - pharmacology
biomarker
Cross-Over Studies
Double-Blind Method
electroencephalogram
Electroencephalography
event-related brain activity
Female
go/no-go association task
Humans
Male
Neuropsychological Tests
power spectral analysis
psychomotor vigilance task
Sleep Deprivation - physiopathology
Wakefulness - drug effects
Wakefulness - physiology
Wakefulness-Promoting Agents - pharmacology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of central nervous system‐acting drugs would be enhanced by suitable biomarkers that reflect the targeted pathophysiologic brain state. The electroencephalogram (EEG) has several characteristics of an ideal biomarker and can be promptly adapted to pre‐clinical and clinical testing. The aim of this study was to evaluate EEG as a measure of the wakefulness‐promoting effect of armodafinil in sleep deprived healthy subjects. Armodafinil pharmacodynamics were simultaneously assessed by EEG‐ and behavioral‐based measures including a well‐established measure of alertness. Using two quantitative EEG‐based measures—power spectral and event‐related brain activity analyses—we observed that armodafinil mitigated the slowing of brain activity and the decrease of the event‐related brain activity caused by sleep deprivation. Armodafinil‐induced changes in EEG are in agreement and explain up to 73.1% of the armodafinil‐induced changes in alertness. Our findings suggest that EEG can serve as a marker of the wakefulness‐promoting drug effect.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.143